Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody.

Garrity ER, Villanueva J, Bhorade SM, Husain AN, Vigneswaran WT. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation. 2001 Mar 27; 71(6):773-7.

View in: PubMed

collapse authors with profiles